KPV peptide: preclinical promise, with no identified human administration study.
KPV has a real molecular identity and a growing preclinical literature. It does not yet have the human evidence needed to turn gut, wound, inflammation, safety, or dosage claims into established clinical facts. This guide keeps each claim beside its exact evidence limit.
KPV is a real peptide. Its popular benefits remain preclinical.
KPV is lysine-proline-valine, a three-amino-acid fragment of alpha-MSH. PubChem identifies the free base as C16H30N4O4 with molecular weight 342.43. FDA separately reviews KPV free base and KPV acetate.
FDA says it found no published study in which a compounded or non-compounded KPV drug product was administered to humans. Cell, mouse, excised-skin, and stability studies cannot close that gap.
Read the KPV record in four fields.
This is a sourced status snapshot, not a safety score, treatment recommendation, or seller certification. Each field links back to the detailed record below.
0 human administration studies
FDA found no published study that administered compounded or non-compounded KPV to people.
Inspect the human evidencePreclinical benefit only
Cell, animal, delivery, and stability records do not establish a human gut, skin, or wound benefit.
Audit the popular claimsNo FDA-approved product
FDA staff currently proposes not adding KPV free base or acetate to the 503A Bulks List.
Check status and destination routesNo normalized price board
Peptide Local does not currently publish a like-for-like KPV research-price board, so no market range is shown.
Identity, preclinical results, human evidence, and FDA status are different records.
The absence of human data is the central fact. It cannot be filled with animal results, seller copy, or a proposed formulation.
A three-amino-acid alpha-MSH fragment
KPV means lysine-proline-valine and is also indexed as MSH 11-13. FDA evaluates KPV free base and KPV acetate as different bulk drug substances. A shared KPV label does not prove which form, formulation, quality, or product is present.
Cells, mice, delivery, and stability
Published records cover cell systems, mouse colitis models, nanoparticle delivery, ex vivo skin transport, and analytical stability. These records can support laboratory hypotheses. They do not establish a human gut, skin, wound, or anti-inflammatory benefit.
No identified human administration study
FDA states that it found no published study in which a compounded or non-compounded KPV product was administered to humans. The dated ClinicalTrials.gov intervention search returned zero records. Human effectiveness, dosing, and routine side-effect rates remain unresolved.
A favorable committee recommendation, not final FDA action
FDA staff proposed not adding KPV free base or KPV acetate to the 503A Bulks List. On July 23, PCAC recommended inclusion after reported 8-6-1 votes on the paired form questions. That advice is nonbinding, does not approve a drug, and does not immediately change the list.
What KPV research shows, and what it cannot prove.
Every popular claim needs both the supporting record and the study-model boundary.
KPV for gut health or IBD
Cell work and mouse colitis models report anti-inflammatory signals and disease-model effects.
No cited record administered KPV to people with inflammatory bowel disease or established clinical benefit, dose, durability, or safety.
KPV for wound healing or skin inflammation
The withdrawn compounding nomination proposed topical 0.1% cream or gel, and laboratory papers studied skin transport and analytical stability.
A proposed formulation, excised-skin transport result, or stability assay is not a human wound-healing or dermatology trial.
KPV is anti-inflammatory
Preclinical papers report activity in cells and animal models.
A mechanism or animal outcome cannot establish a treatment effect, appropriate patient group, product, route, or risk profile in humans.
KPV has few side effects
FDA found no human administration study from which a clinical adverse-event profile could be estimated.
Missing adverse-event data does not mean zero adverse events. FDA also identifies unresolved aggregation and immunogenicity questions.
Four studies, none a human KPV treatment trial.
“Human skin,” “human cells,” or a PubMed human indexing term does not mean KPV was administered to a human participant.
KPV transport and anti-inflammatory activity
Supports a preclinical inflammation hypothesis, not a demonstrated human benefit.
KPV in two models of intestinal inflammation
Animal disease-model evidence cannot supply human effectiveness, dose, or safety.
KPV delivery across microporated human skin
Ex vivo delivery evidence is not administration to a study participant or proof of wound healing.
KPV analytical method and stability
A measurement and stability paper does not test clinical efficacy or tolerability.
The July 23 recommendation is meaningful, but it is not approval or final action.
The status should be updated after the committee materials and any later FDA determination are published.
Do not add either KPV form
FDA proposes not adding KPV free base or KPV acetate to the 503A Bulks List based on the current record.
Read the briefing →Favorable committee recommendation
PCAC recommended inclusion of both reviewed forms after reported 8-6-1 votes. The advice is nonbinding, does not approve KPV, and does not immediately change the 503A Bulks List.
Open the verified vote record →Final FDA determination
FDA can complete its review after the advisory process. Until then, the proposal must remain labeled as a proposal.
Track every substance →KPV status must be checked country by country.
Product registration, compounding rules, pharmacy verification, seller records, and import controls vary by destination. Start with the exact KPV identity, then use the official records for the country or jurisdiction where the product would be supplied.
Eight KPV questions, answered without upgrading preclinical evidence.
This is educational reporting, not medical advice, a prescription, or a use protocol.
What is KPV peptide?
KPV is the tripeptide lysine-proline-valine, also described as the 11-13 fragment of alpha-melanocyte-stimulating hormone. PubChem lists formula C16H30N4O4 and molecular weight 342.43 for the free-base identity. FDA separately evaluates KPV free base and KPV acetate, so the short name alone does not resolve the exact substance or formulation.
What are the proven benefits of KPV?
No human therapeutic benefit is established by the cited record. Laboratory and animal studies support hypotheses involving inflammatory pathways, colitis models, delivery, and stability. FDA states that it found no published study in which a KPV drug product was administered to humans. Promising preclinical evidence should not be rewritten as a proven gut, skin, or wound benefit.
Does KPV help gut health or inflammatory bowel disease?
The cited papers include cell systems and mouse colitis models, so there is a real preclinical research trail behind many gut and anti-inflammatory claims. There is not a cited human administration study showing that KPV treats inflammatory bowel disease, improves symptoms, changes clinical outcomes, or has an established dose and safety profile in people.
Does KPV improve wound healing?
FDA reviewed a nomination that proposed topical KPV for wound healing and inflammatory conditions, but the nomination was withdrawn. Laboratory work on excised skin and formulation stability does not establish faster healing or safety in human participants. The FDA briefing says adequate human effectiveness information was not available.
What are KPV side effects?
A reliable clinical side-effect rate cannot be calculated from the current record because FDA found no published human administration study. That absence is an evidence gap, not evidence of safety. FDA also notes unresolved questions around aggregation, immunogenicity, route, formulation, and exposure for the reviewed bulk drug substances.
Is KPV FDA approved?
No FDA-approved KPV drug is established by the cited FDA record. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug. FDA staff proposed non-inclusion, but PCAC recommended inclusion after reported 8-6-1 votes on July 23, 2026. That advice is nonbinding, does not immediately change the list, and is not FDA approval or a final agency decision.
What is the correct KPV dosage?
There is no FDA-approved KPV dosage established for the products discussed here. Cell concentrations, mouse regimens, proposed compounding concentrations, and ex vivo delivery experiments cannot be converted into a self-use protocol. This guide does not provide reconstitution, dosing, injection, topical-use, or stacking instructions for an unapproved substance.
Can you buy KPV legally in my country?
A seller page, research label, local currency, or shipping claim cannot answer that. Product authorization, compounding rules, prescription controls, import rules, pharmacy licensing, seller identity, and the exact free-base or acetate form must be checked in the destination's official records. Use the country and subnational maps below for those separate checks.
No human dosage or safety profile can be extracted from a mouse or laboratory study.
Route, form, formulation, concentration, aggregation, immunogenicity, quality, exposure, population, and endpoints all matter. FDA identifies unresolved safety and characterization questions and says adequate human administration information was not found.
A research listing, proposed compounded formulation, preclinical paper, and FDA-reviewed bulk drug substance are different evidence records. None supplies an approved product label or a self-use protocol.